Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

HLB Life Science Co stock

067630.KQ
KR7067630004

Price

6,570.00
Today +/-
-0.13
Today %
-3.00 %

HLB Life Science Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the HLB Life Science Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the HLB Life Science Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the HLB Life Science Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze HLB Life Science Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

HLB Life Science Co Stock Price History

DateHLB Life Science Co Price
3/28/20256,570.00 undefined
3/27/20256,770.00 undefined
3/26/20256,650.00 undefined
3/25/20256,860.00 undefined
3/24/20257,030.00 undefined
3/21/20255,990.00 undefined
3/20/20258,550.00 undefined
3/19/20259,000.00 undefined
3/18/20259,470.00 undefined
3/17/20259,460.00 undefined
3/14/20258,960.00 undefined
3/13/20259,090.00 undefined
3/12/20259,950.00 undefined
3/11/20259,730.00 undefined
3/10/20259,720.00 undefined
3/7/202510,490.00 undefined
3/6/202510,400.00 undefined
3/5/202510,850.00 undefined
3/4/202510,970.00 undefined

HLB Life Science Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into HLB Life Science Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by HLB Life Science Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects HLB Life Science Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of HLB Life Science Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into HLB Life Science Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing HLB Life Science Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on HLB Life Science Co’s growth potential.

HLB Life Science Co Revenue, EBIT and net profit per share

DateHLB Life Science Co RevenueHLB Life Science Co EBITHLB Life Science Co Net Income
202397.99 B undefined-24.53 B undefined-5.98 B undefined
202299.59 B undefined-20.16 B undefined-54.28 B undefined
202153.49 B undefined-18.48 B undefined-49.15 B undefined
202091.8 B undefined-8.07 B undefined-55.8 B undefined
2019114.02 B undefined-4.48 B undefined-7.61 B undefined
2018102.48 B undefined-7.96 B undefined-3.07 B undefined
2017106.45 B undefined989 M undefined7.76 B undefined
201642.23 B undefined-1.4 B undefined-1.25 B undefined
201527.32 B undefined-9.7 B undefined-17.04 B undefined
201436.56 B undefined1.45 B undefined1.4 B undefined
201319.96 B undefined-3.2 B undefined-4.07 B undefined
20129 B undefined-4.67 B undefined-8.35 B undefined
201140.95 B undefined-2.19 B undefined-4.02 B undefined

HLB Life Science Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2011201220132014201520162017201820192020202120222023
40.95919.9636.5627.3242.23106.45102.48114.0291.853.4999.5997.99
--78.03121.7883.20-25.2754.57152.04-3.7311.26-19.49-41.7386.17-1.61
5.333.501.0514.31-16.437.825.094.566.672.53-10.35-3.06-0.76
2.180.320.215.23-4.493.35.414.677.612.33-5.54-3.05-0.75
-4.02-8.35-4.071.4-17.04-1.257.76-3.07-7.61-55.8-49.15-54.28-5.98
-107.56-51.21-134.44-1,314.61-92.66-720.38-139.51148.04633.69-11.9110.43-88.98
16161728345151578894105.15106.88107.73
-------------
Details

Keystats

ⓘ

Revenue and Growth

The HLB Life Science Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the HLB Life Science Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (B)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (B)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (B)
UNREAL. GAINS/LOSSES (B)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (B)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
201120122013201420152016201720182019202020212022
                       
4.634.25.164.9423.0613.3830.26194.79175.76158.03139.96128.27
22.6613.1910.616.413.7331.7631.9632.3938.4917.7611.7912.94
0.920.461.381.481.082.46.81.852.252.062.684.36
00.9502.653.457.184.915.857.152.081.7710.87
0.620.4918.551.650.690.250.524.20.031.390.634.34
28.8319.2835.717.1232.0254.9674.45239.09223.67181.33156.82160.78
2.3910.113.083.543.383.593.280.7523.0622.9422.0892.09
2.412.552.341.912.5818.318.1223.3560.3944.4328.1465.24
27.6612.37.065.513.71.630.541.251.430.690.480.48
0.050.040.055.321.033.621.5271.8773.7575.4462.8169.51
000000.590.5948.822.61.9021.92
1.561.600000.521.160.040.480.471.78
34.0626.5912.5316.2710.6827.7224.57147.17181.27145.87113.98251.01
62.8945.8748.2333.3942.782.6899.02386.25404.94327.2270.8411.79
                       
3.243.246.747.1512.3112.3113.8118.622424.0148.2248.83
12.812.548.044.2229.1632.1831.99200.89284.03284.11230.88209.44
-0.18-8.22-3.971.39-15.57-16.86.643.55-0.19-59.85-46.45-40.7
-0.05-0.02-0.010.68-000.41-0.50.354.063.997.56
-0.0800.2300-0.01-0.02-3.4725.6434.859.559.59
15.737.5411.0413.4425.8927.6952.83219.09333.82287.18246.19234.72
4.72.496.824.055.327.5529.7622.8126.735.5510.289.38
1432484600793278429566584717.82697.15
4.76.3710.124.745.792.853.8411.7811.1511.361.876.25
6.967.7941.043.273.971.081.410.7007.92
11.127.028.675.40.171.561.612.220.70.380.672.53
27.6123.929.6615.2314.5336.7236.5548.6439.8417.8713.5426.78
19.5512.886.94.342.1617.648.7280.0710.5811.013.95137.02
000000.230.514.1210.239.675.7610.03
0.492.050.640.380.120.410.4222.189.870.910.941.88
20.0414.937.534.722.2718.279.64116.3830.6721.5910.65148.94
47.6538.8337.1919.9516.8154.9946.19165.0270.5139.4524.19175.72
63.3846.3748.2333.3942.782.6899.02384.1404.33326.64270.38410.45
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of HLB Life Science Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand HLB Life Science Co's financial health and stability.

Assets

HLB Life Science Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that HLB Life Science Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of HLB Life Science Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into HLB Life Science Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-4.02-8.35-4.071.4-17.04-1.257.76-3.3-7.56-55.84-49.29-54.36
0.060.350.560.540.710.350.320.31.822.162.415.12
000000000000
11.3320.573.495.894.29-2.52-0.6-5.17-10.516.251.51-13.9
2.661.42.752.617.71.15-7.78-2.913.8649.4331.2933.4
0000000000250674
0.61-0.030.010.020.160.080.280.050.860.21-0.571.14
10.0313.972.7210.43-4.34-2.27-0.3-11.07-12.392.01-14.08-29.74
-317-9,181-81-542-688-1,300-307-10,537-15,486-20,808-2,610-11,653
1.51-5.37-1.4-1.66-6.45-252.24-162.0454.060.068.82-72.64
1.833.81-1.32-1.12-5.76-23.72.55-151.569.5420.8711.43-60.99
000000000000
-10.17-9.97-7.23-10.33-0.9715.847.3823.73-5.04-1.77-0.64101.1
-3.5207.19124.9700154.280.640.080.130.2
-13.74-9.970.24-8.6923.9915.847.35176.53-21.75-1.68-0.64102.1
-550283628-150-30-1,473-17,3520-128800
000000000000
-2.2-1.371.560.0813.2-11.439.293.4219.910.39-5.9-0.28
9,7144,7872,6439,890-5,029-3,573-609-21,610-27,874-18,798-16,694.17-41,397.47
000000000000

HLB Life Science Co stock margins

The HLB Life Science Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HLB Life Science Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HLB Life Science Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the HLB Life Science Co's sales revenue. A higher gross margin percentage indicates that the HLB Life Science Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the HLB Life Science Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the HLB Life Science Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the HLB Life Science Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the HLB Life Science Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the HLB Life Science Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

HLB Life Science Co Margin History

HLB Life Science Co Gross marginHLB Life Science Co Profit marginHLB Life Science Co EBIT marginHLB Life Science Co Profit margin
2023-0.76 %-25.04 %-6.11 %
2022-3.06 %-20.24 %-54.5 %
2021-10.35 %-34.55 %-91.88 %
20202.53 %-8.79 %-60.78 %
20196.67 %-3.93 %-6.67 %
20184.56 %-7.77 %-2.99 %
20175.09 %0.93 %7.29 %
20167.82 %-3.31 %-2.96 %
2015-16.43 %-35.49 %-62.37 %
201414.31 %3.97 %3.84 %
20131.05 %-16.04 %-20.41 %
20123.5 %-51.94 %-92.8 %
20115.33 %-5.34 %-9.82 %

HLB Life Science Co Stock Sales Revenue, EBIT, Earnings per Share

The HLB Life Science Co earnings per share therefore indicates how much revenue HLB Life Science Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue HLB Life Science Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HLB Life Science Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HLB Life Science Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HLB Life Science Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

HLB Life Science Co Revenue, EBIT and net profit per share

DateHLB Life Science Co Sales per ShareHLB Life Science Co EBIT per shareHLB Life Science Co Earnings per Share
2023909.57 undefined-227.72 undefined-55.54 undefined
2022931.84 undefined-188.64 undefined-507.86 undefined
2021508.72 undefined-175.75 undefined-467.42 undefined
2020976.56 undefined-85.81 undefined-593.59 undefined
20191,295.67 undefined-50.9 undefined-86.42 undefined
20181,797.82 undefined-139.7 undefined-53.79 undefined
20172,087.16 undefined19.39 undefined152.18 undefined
2016828.12 undefined-27.41 undefined-24.53 undefined
2015803.62 undefined-285.18 undefined-501.21 undefined
20141,305.71 undefined51.82 undefined50.11 undefined
20131,173.88 undefined-188.29 undefined-239.65 undefined
2012562.38 undefined-292.13 undefined-521.88 undefined
20112,559.56 undefined-136.75 undefined-251.44 undefined

HLB Life Science Co business model

HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies. HLB Life Science Co is one of the most popular companies on Eulerpool.com.

HLB Life Science Co SWOT Analysis

Strengths

HLB Life Science Co Ltd possesses several strengths that contribute to its success in the life science industry. These strengths include:

  • Strong research and development capabilities
  • Extensive portfolio of innovative products
  • Established reputation for quality and reliability
  • Well-trained and highly skilled workforce
  • Strong financial position and stable revenue streams

Weaknesses

Despite its strengths, HLB Life Science Co Ltd also faces certain weaknesses that pose challenges to its growth and competitiveness. These weaknesses include:

  • Reliance on a limited number of key customers
  • Relatively small market share compared to industry giants
  • Limited global presence and market penetration
  • Higher production costs compared to some competitors
  • Lack of diversification in its product offerings

Opportunities

HLB Life Science Co Ltd can leverage a number of opportunities in the market to drive growth and expansion. These opportunities include:

  • Increasing demand for advanced life science products
  • Emerging markets with untapped potential
  • Rapid advancements in technology and innovation
  • Potential collaborations and partnerships for product development
  • Growing emphasis on sustainability and eco-friendly solutions

Threats

HLB Life Science Co Ltd faces various threats that can impact its business operations and market position. These threats include:

  • Intense competition from larger and established industry players
  • Economic uncertainty and fluctuations
  • Stringent regulatory requirements
  • Potential disruption of global supply chains
  • Rapid changes in customer preferences and market trends
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

HLB Life Science Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

HLB Life Science Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

HLB Life Science Co shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue HLB Life Science Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HLB Life Science Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HLB Life Science Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HLB Life Science Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

HLB Life Science Co stock splits

In HLB Life Science Co's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for HLB Life Science Co.

HLB Life Science Co shareholders

%
Name
Stocks
Change
Date
16.97902 % HLB Co., Ltd.20,695,72509/30/2024
2.30213 % The Vanguard Group, Inc.2,806,06827,5211/31/2025
1.79483 % Samsung Asset Management Co., Ltd.2,187,7191831/31/2025
0.96253 % BlackRock Institutional Trust Company, N.A.1,173,23201/31/2025
0.35840 % Mirae Asset Global Investments Co., Ltd.436,852-991/31/2025
0.30945 % BlackRock Advisors (UK) Limited377,1833931/31/2025
0.24305 % Dimensional Fund Advisors, L.P.296,251-19,50812/31/2024
0.20233 % State Street Global Advisors (US)246,62101/31/2025
0.15357 % Charles Schwab Investment Management, Inc.187,188011/30/2024
0.13617 % KB Asset Management Co., Ltd.165,974-4521/31/2025
1
2
3
4

Most common questions regarding HLB Life Science Co

What values and corporate philosophy does HLB Life Science Co represent?

HLB Life Science Co Ltd represents a strong commitment to innovation and excellence in the field of life sciences. Their corporate philosophy revolves around advancing medical solutions through cutting-edge research and development. By harnessing scientific expertise and technological advancements, HLB Life Science strives to contribute to the well-being of society by providing high-quality healthcare products and services. With a relentless focus on customer satisfaction and ethical business practices, the company aims to become a trusted leader in the life sciences industry. HLB Life Science Co Ltd's dedication to scientific advancement and social responsibility is reflected in their commitment to delivering innovative solutions for a healthier future.

In which countries and regions is HLB Life Science Co primarily present?

HLB Life Science Co Ltd is primarily present in the Asian region. It has a strong presence in countries such as China, Japan, South Korea, and Taiwan. With its headquarters based in Japan, HLB Life Science Co Ltd has strategically expanded its operations across these countries to capitalize on the growing demand for life science solutions. As a leading company in the industry, HLB Life Science Co Ltd continues to strengthen its market position and deliver innovative products and services to its customers in these regions.

What significant milestones has the company HLB Life Science Co achieved?

HLB Life Science Co Ltd has achieved significant milestones in its journey. Some noteworthy accomplishments include successful development of innovative solutions in the field of life sciences, groundbreaking research and development initiatives, strategic partnerships with global industry leaders, and continuous expansion of its product portfolio. The company's commitment to quality, innovation, and customer satisfaction has led to widespread recognition and accolades. With its tireless efforts and strong market presence, HLB Life Science Co Ltd has become a trusted name in the life sciences industry.

What is the history and background of the company HLB Life Science Co?

HLB Life Science Co Ltd is a prominent company in the life science industry. Founded in [year], the company has grown steadily over the years. HLB Life Science Co Ltd specializes in [specific area of focus], providing innovative solutions and services to its customers. With a strong background in research and development, the company has achieved significant milestones, including [mention any notable achievements or breakthroughs]. HLB Life Science Co Ltd is committed to advancing scientific knowledge and improving the quality of life for people worldwide. With its expertise and dedication, the company continues to make a positive impact in the field of life science.

Who are the main competitors of HLB Life Science Co in the market?

The main competitors of HLB Life Science Co Ltd in the market include other leading companies in the life science industry. These competitors may include companies such as XYZ Biotech, ABC Pharmaceuticals, and DEF Genetics. These companies also focus on developing innovative drugs, conducting research, and delivering cutting-edge solutions in the life science sector. HLB Life Science Co Ltd faces tough competition but continues to strive for excellence and maintain its position as a prominent player in the industry.

In which industries is HLB Life Science Co primarily active?

HLB Life Science Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of HLB Life Science Co?

The business model of HLB Life Science Co Ltd focuses on the development and commercialization of innovative pharmaceutical products. As a leading biopharmaceutical company, HLB Life Science Co Ltd aims to improve the quality of life by researching, discovering, and providing effective treatments for various diseases and medical conditions. With a strong emphasis on research and development, the company utilizes advanced technologies and scientific expertise to produce novel drugs and therapies. HLB Life Science Co Ltd strives to establish strategic partnerships, expand its product portfolio, and contribute to the advancement of healthcare globally through its innovative business model.

What is the P/E ratio of HLB Life Science Co 2025?

The P/E ratio cannot be calculated for HLB Life Science Co at the moment.

What is the P/S ratio of HLB Life Science Co 2025?

The P/S cannot be calculated for HLB Life Science Co currently.

What is the Quality Investing of HLB Life Science Co?

The Quality Investing for HLB Life Science Co is 4/10.

What is the revenue of HLB Life Science Co 2025?

The revenue cannot currently be calculated for HLB Life Science Co.

How high is the profit of HLB Life Science Co 2025?

The profit cannot currently be calculated for HLB Life Science Co.

What is the business model of HLB Life Science Co

HLB Life Science Co Ltd is a company specialized in biotechnological research and product development. It aims to provide innovative solutions to customers worldwide to enhance their health and well-being. The company is divided into several divisions focusing on different aspects of biotechnological research, including the development of new drugs, the production of pharmaceuticals and supplements, and services in pharmaceutical analytics. HLB Life Science offers a wide range of tailored products, such as supplements, medications for various diseases and disorders, diagnostic and testing kits for monitoring health issues, and analytical tools for pharmaceutical research. The company has a good reputation with positive customer reviews, thanks to its high product quality and customer service. With a strong research and development team, HLB Life Science can develop innovative products that meet the changing needs of its customers. It collaborates closely with partner companies and other organizations to promote growth and success. The company also has a strong online presence, with customers worldwide able to purchase and utilize its products and services. By utilizing search engine optimization and other digital marketing strategies, HLB Life Science ensures its online visibility and accessibility to potential customers. Overall, HLB Life Science's business model focuses on developing and offering innovative solutions for the healthcare industry. With its strong research and development department and partnership collaborations, the company aims to benefit customers worldwide. With a wide range of products and high-quality customer service, HLB Life Science has achieved success in a competitive field.

What is the HLB Life Science Co dividend?

HLB Life Science Co pays a dividend of 0 KRW distributed over payouts per year.

How often does HLB Life Science Co pay dividends?

The dividend cannot currently be calculated for HLB Life Science Co or the company does not pay out a dividend.

What is the HLB Life Science Co ISIN?

The ISIN of HLB Life Science Co is KR7067630004.

What is the HLB Life Science Co ticker?

The ticker of HLB Life Science Co is 067630.KQ.

How much dividend does HLB Life Science Co pay?

Over the past 12 months, HLB Life Science Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Life Science Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of HLB Life Science Co?

The current dividend yield of HLB Life Science Co is .

When does HLB Life Science Co pay dividends?

HLB Life Science Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of HLB Life Science Co?

HLB Life Science Co paid dividends every year for the past 0 years.

What is the dividend of HLB Life Science Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is HLB Life Science Co located?

HLB Life Science Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von HLB Life Science Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HLB Life Science Co from 3/30/2025 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 3/30/2025.

When did HLB Life Science Co pay the last dividend?

The last dividend was paid out on 3/30/2025.

What was the dividend of HLB Life Science Co in the year 2024?

In the year 2024, HLB Life Science Co distributed 0 KRW as dividends.

In which currency does HLB Life Science Co pay out the dividend?

The dividends of HLB Life Science Co are distributed in KRW.

All fundamentals about HLB Life Science Co

Our stock analysis for HLB Life Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Life Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.